转移性肾细胞癌中RECIST 1.1靶病灶分类反应:传统评估与体积评估的比较
本研究为回顾性队列研究,纳入2003至2017年一项临床试验中转移性肾细胞癌患者,比较基于RECIST 1.1直径的球形模型体积与手动勾画实际体积对靶病灶分类治疗反应的差异。结果显示基于单一直径的RECIST 1.1模型在第9周和第17周将更多患者分类为进展性疾病,总体反应不一致性显著(P < .001)。
要点
- 基于RECIST直径的球形模型体积较实际勾画体积更常将患者分类为进展性疾病。
- 第9周时,球形模型判定为进展性疾病的52例中,有25例(48%)被实际体积分类为疾病稳定。
- 第9周和第17周总体反应分类不一致性显著(P < .001)。
核心结论
- 基于单一直径测量的RECIST 1.1模型体积较实际测量肿瘤体积更频繁地将患者分类为进展性疾病。
研究设计与样本
- 回顾性队列研究,纳入2003至2017年一项临床试验(ClinicalTrials.gov注册号NCT01865747)中的转移性肾细胞癌患者,基线638例、第9周593例、第17周508例接受胸腹盆腔CT检查且有至少一个靶病灶;比较基于RECIST直径外推的球形模型体积(Vmodel)与手动勾画实际体积(Vactual)的靶病灶体积总和分类反应。
诊断标准与关键数值
- 体积分类阈值由RECIST外推;Vmodel-sum TL在第9周将52例分类为进展性疾病,Vactual-sum TL为31例;第17周分别为57例和39例;第9周Vmodel-sum TL判定为进展性疾病的52例中,25例(48%)被Vactual-sum TL分类为疾病稳定;总体反应不一致性P < .001。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To investigate Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) approximations of target lesion tumor burden by comparing categorical treatment response according to conventional RECIST versus actual tumor volume measurements of RECIST target lesions. Materials and Methods This is a retrospective cohort study of individuals with metastatic renal cell carcinoma enrolled in a clinical trial (from 2003 to 2017) and includes individuals who underwent baseline and at least one follow-up chest, abdominal, and pelvic CT study and with at least one target lesion. Target lesion volume was assessed by (a) Vmodel, a spherical model of conventional RECIST 1.1, which was extrapolated from RECIST diameter, and (b) Vactual, manually contoured volume. Volumetric responses were determined by the sum of target lesion volumes (Vmodel-sum TL and Vactual-sum TL, respectively). Categorical volumetric thresholds were extrapolated from RECIST. McNemar tests were used to compare categorical volume responses. Results Target lesions were assessed at baseline (638 participants), week 9 (593 participants), and week 17 (508 participants). Vmodel-sum TL classified more participants as having progressive disease (PD), compared with Vactual-sum TL at week 9 (52 vs 31 participants) and week 17 (57 vs 39 participants), with significant overall response discordance (P < .001). At week 9, 25 (48%) of 52 participants labeled with PD by Vmodel-sum TL were classified as having stable disease by Vactual-sum TL. Conclusion A model of RECIST 1.1 based on a single diameter measurement more frequently classified PD compared with response assessment by actual measured tumor volume. Keywords: Urinary, Kidney, Metastases, Oncology, Tumor Response, Volume Analysis, Outcomes Analysis ClinicalTrials.gov registration no. NCT01865747 © RSNA, 2023 Supplemental material is available for this article.
引用
- Gong AJ, Ruchalski K, Kim HJ, et al. RECIST 1.1 Target Lesion Categorical Response in Metastatic Renal Cell Carcinoma: A Comparison of Conventional versus Volumetric Assessment. Radiol Imaging Cancer. 2023. PMID: 37656041. doi:10.1148/rycan.220166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。